Will US FDA Offer Regulatory Flexibility For ANDAs Downgraded Because Of CRO Investigation?

 
• By Derrick Gingery
  
Two doors, two choices
The FDA is offering most sponsors two doors, redoing the BE studies or withdrawing the application, but each has its own challenges. • Source: Alamy

More from Generics

More from Biosimilars & Generics